High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia
Authors:
Open Access
- 14 February 2005
- journal article
- clinical trial
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 35 (7) , 653-661
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemiaBone Marrow Transplantation, 2000
- Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphomaBone Marrow Transplantation, 2000
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapyBone Marrow Transplantation, 1998
- Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: Risk factors for early regimen-related toxicityAnnals of Hematology, 1994
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988
- The Clinical Pharmacology of Etoposide and TeniposideClinical Pharmacokinetics, 1987
- High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemiaCancer, 1987
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958